Abstracts OBJECTIVES: To estimate direct medical costs and treatment failure rates associated with use of systemic agents and phototherapy in moderate to severe psoriasis. METHODS: Patient-level claims data on use of psoriasis-related Health care services were obtained from a large New England payer. Patients with >1 claim listings a ICD-9-CM diagnosis code for psoriasis (696.0; 696.1) were eligible for inclusion. Eligible patients not receiving systemic treatments (methotrexate, cyclosporin A, acitretin) or phototherapy (ultraviolet B with or without tar or petrolatum; psoralen and ultraviolet A [PUVA]) were excluded. Treatment failure was defined as switch to nonrotational therapy, augmentation with nontopical therapies, discontinuation following up-titration, or discontinuation following hospitalization for psoriasis. Medical costs included those related to pharmacy (excluding OTC medication), institutional (inpatient and outpatient) care, and professional services. Mean costs within each service category, as well as 99th percentile costs, were estimated by treatment. RESULTS: A total of 2073 patients were included in the analysis. Over a 1-year period, approximately 21.7% of patients experienced treatment failure, with therapy switches accounting for most occurrences. Mean time to treatment failure ranged from 3-6 months. Per-patient annual pharmacy costs were lowest among methotrexate users (US$257) and highest among cyclosporin users (US$1992). The 99th percentile of annual pharmacy and institutional costs exceeded US$10,000, while that of professional service costs was approximately US$2,500. CONCLUSIONS: The high variability of direct medical costs among these patients reflects the heterogeneous and chronic nature of psoriasis. Overall, use of conventional systemic and light therapies for treatment of moderate to severe psoriasis was associated with frequent failure and high medical costs.
OBJECTIVES:
Examining the economic impact of psoriasis vulgaris during the course of one year and due to a current skin deterioration (flare). METHODS: A multicenter, cross-sectional, retrospective, and prospective cost-of-illness study. Information such as demographic characteristics, frequency, and number of consultations, hospitalizations, rehabilitations, out-of-pocketexpenditures and absence from work were collected by semi-standardized patient questionnaires and chart record reviews (12 months retrospectively; 6 weeks prospectively). Direct, medical and non-medical, and indirect costs were considered from several perspectives: patients', third party payers' (TPP), societal. Inclusion criteria: moderate to severe chronic plaque psoriasis, age (18-65 years), ongoing flare, signed informed consent. RESULTS: Twelve office-based dermatologists and 5 outpatient departments in dermatology hospitals enrolled 227 patients, 56% with moderate and 44% with severe course of disease. Eighty-six percent of the patients responded to the questionnaire. Mean age was 47 years, 55% were male. On average, annually TPP reimbursed €835 per patient. Main cost drivers were prescribed medication (60%) and hospitalization (22%). Patients spent €596 p.a. mainly for additional treatments (26%) e.g. alternative therapy, OTC-medication/skin care (29%). Indirect costs per patient amounted to €1435 p.a., 92% related to early retirement/unemployment due to psoriasis. Total annual costs per patient were €2866, including €2658 per patient with moderate and €2852 per patient with severe course of disease. Due to the current flare 32% of the patients received systemic therapy and 61% were treated exclusively topically and/or with phototherapy. Direct medical costs (TPP) due to a current flare amounted to €195 per patient within 6 weeks; including €449 per patient treated with systemic drugs and €85 treated locally and/or with phototherapy. CONCLU-SION: Patients and their families bear a sizeable amount themselves. Also, the burden for TPP and for society is noticeable. Costs increased remarkably for patients receiving systemic therapy.
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PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM INFLAMMATORY DERMATITIS (PSORIASIS, ECZEMA, ATOPIC DERMATITIS AND URTICARIA) IN FRANCE-INSTANT STUDY
Wolkenstein P 1 , Crochard A 2 , Mimaud V 3 , Stalder JF 4 , Lorette G 5 , El Hasnaoui A 6 1 Henri Mondor Hospital, Créteil, France; 2 GlaxoSmithKline, Marly Le Roy, France; 3 CEMKA, Bourg la Reine, France; 4 Hôtel Dieu Hospital, Nantes, France; 5 Trousseau Hospital, Tours, France; 6 laboratory GSK, Marly Le Roi, France OBJECTIVES: To estimate the prevalence and the quality of life of subjects suffering from inflammatory dermatitis (ID) (psoriasis, eczema, atopic dermatitis and urticaria) in the French population of adults 18 years of age or older. METHODS: A population-based survey was conducted among 10,000 adults through personal face to face interviews by using the quota sampling method (applied on age, sex, economic working class and woman working status). The screening was made by asking the subjects if they have suffered from one of the 4 ID in the past 12 months or if they have been treated by at least one inflammatory dermatitis specific treatment from a pre-defined list. Subjects answering positively to one of these questions was considered as a "ID subject". The quality of life was assessed by using the SF-36 questionnaire among the ID subjects and a randomly selected control group of subjects not suffering from ID (520 persons). RESULTS: The population surveyed was representative of the French population in terms of age, sex, and geographic living area. Patients suffering from ID were similar to the control group in terms of age, sex, and geographic living area. The annual prevalence of ID was estimated: 8.8%, IC 95% = [7.8%; 9.8%]. The SF-36 score of mental health was significantly lower in the ID population: 45.8 versus 48.0 in the control group (p < 0,001). The SF-36 score of physical health was not significantly different. CONCLUSION: The annual prevalence of inflammatory dermatitis is estimated at 9% in French adult population. People suffering from inflammatory dermatitis have a significant impact on the mental health dimension of quality of life but not on physical dimension.
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THE USE OF DISCRETE CHOICE ANALYSIS TO ASSIST WITH THE INTERPRETATION OF QUALITY OF LIFE SCORES
Backhouse ME 1 , Meads D 2 , Doward LC 2 , McKenna SP 2 1 Novartis Pharma AG, Basel, Switzerland; 2 Galen Research, Manchester, United Kingdom OBJECTIVE: A common approach to the problem of interpreting the clinical implications of quality of life (QoL) scores is to utilize the concept of minimal important difference (MID). MID emphasises both the primacy of patient preferences and the relation between QoL scores and treatment change. The study purpose is to illustrate how discrete choice analysis (DCA) could be used to estimate the relation between QoL and patient preferences for treatment change. METHODS: A 28-item atopic dermatitis (AD) QoL instrument was applied to 102 subjects enrolled in a pivotal trial comparing two alternative AD treatments. Four QoL assessments were made over 12 months. Subjects were also asked to indicate the extent to which the disease was under control. Their responses were dichotomized into a variable, which indicated whether subjects were inclined to seek treatment change, or not. DCA was used to estimate the relation between probability of treatment change and QoL scores. RESULTS: QoL scores were found to be a statistically significant predictor of the probability that a subject would seek a treatment change (p < 0.0001 in each case). The sign on the QoL coefficient was in line with prior expectations. For both treatments, the probability that a subject would seek a treatment change declined over time (from 0.63 to 0.42 for active treatment; 0.63 to 0.57 for comparator). However, the probability for the new treatment under investigation was lower at the end of the trials than for the comparator. CONCLUSIONS: While our analysis is illustrative and exploratory, the results suggest that DCA offers a promising approach to the interpretation of QoL scores. By modeling the direct relation between QoL scores and a patient's desire for treatment change, the approach dispenses with the need for anchor measures, the interpretation of which is often unclear. 
OBJECTIVES:
The objective of the analysis is to evaluate the willingness to pay for topical psoriasis treatment in Denmark. METHODS: A stated preference methoddiscrete choice experiment (DCE) was applied as a postal survey to 700 members of the Danish Psoriasis Association. The respondents were asked to choose between two hypothetical treatment options. The treatment options were described by six attributes: Number of products, frequency of application, visual effects, non-visual effects, three types of side effects and monthly cost. Through logistic regression it was possible to extract the willingness-to-pay of each attribute and for specific marketed treatment options (defined by these attributes). RESULTS: The survey had a high response rate (73%, or N = 510), and showed the highest willingness-to-pay for avoidance of two named side effects (irritated skin and thin skin) followed by visual effect of the treatment. After adjusting results of the logistic regression model for income, the willingness to pay for the best possible treatment option relative to the worst possible treatment option was DKK 4443 (=€597) per month. The willingness to pay for for a newly launched topical treatment option containing calcipotriol and bethamethasone (Daivobet) would thus be DKK 4043 (=€543) compared to an estimated monthly treatment cost of DKK 683 (=€92). Thus, the societal welfare gain of a month of Daivobet treatment is DKK 3360 (=€452). CONCLU-SION: The survey showed high willingness to pay among a group of Danish psoriasis patients, especially for avoided side effects and effective treatment. For a single product (calcipotriol/bethamethasone (Daivobet)), the willingness-to-pay proved more than fourfold as high as the treatment cost.
